These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 30683103)

  • 21. Linking Women Experiencing Incarceration to Community-Based HIV Pre-Exposure Prophylaxis Care: A Qualitative Study.
    Ramsey SE; Ames EG; Uber J; Habib S; Hunt L; Brinkley-Rubinstein L; Teitelman AM; Clarke J; Kaplan C; Phillips NJ; Murphy M
    AIDS Educ Prev; 2021 Jun; 33(3):216-233. PubMed ID: 34014108
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relationship Type and Use of the Vaginal Ring for HIV-1 Prevention in the MTN 020/ASPIRE Trial.
    Pleasants E; Tauya T; Reddy K; Mirembe BG; Woeber K; Palanee-Phillips T; Zimba C; Atujuna M; Montgomery ET;
    AIDS Behav; 2020 Mar; 24(3):866-880. PubMed ID: 31111297
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Willingness to participate in future HIV prevention trials in Beira, Mozambique.
    Meque I; Dubé K; Bierhuizen L; Zango A; Veldhuijzen N; Cumbe F; Feldblum PJ; van de Wijgert J
    Afr J AIDS Res; 2014; 13(4):393-8. PubMed ID: 25555105
    [TBL] [Abstract][Full Text] [Related]  

  • 24. "Set it and forget it": women's perceptions and opinions of long-acting topical vaginal gels.
    van den Berg JJ; Rosen RK; Bregman DE; Thompson LA; Jensen KM; Kiser PF; Katz DF; Buckheit K; Buckheit RW; Morrow KM
    AIDS Behav; 2014 May; 18(5):862-70. PubMed ID: 24248674
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Women and ARV-based HIV prevention - challenges and opportunities.
    Geary CW; Bukusi EA
    J Int AIDS Soc; 2014; 17(3 Suppl 2):19356. PubMed ID: 25224621
    [TBL] [Abstract][Full Text] [Related]  

  • 26. User-identified gel characteristics: a qualitative exploration of perceived product efficacy of topical vaginal microbicides.
    Morrow KM; Underhill K; van den Berg JJ; Vargas S; Rosen RK; Katz DF
    Arch Sex Behav; 2014 Oct; 43(7):1459-67. PubMed ID: 24452632
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hygiene, Blood Flow, and Vaginal Overload: Why Women Removed an HIV Prevention Vaginal Ring During Menstruation in Malawi, South Africa, Uganda and Zimbabwe.
    Duby Z; Katz AWK; Browne EN; Mutero P; Etima J; Zimba CC; Woeber K; Atujuna M; Reddy K; van der Straten A;
    AIDS Behav; 2020 Feb; 24(2):617-628. PubMed ID: 31030301
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Women design their own vaginal microbicide trial: Suggestions on how to improve adherence from former participants of HIV prevention trials.
    Miller L; Morar N; Kapiga S; Ramjee G; Hayes R
    PLoS One; 2021; 16(1):e0244652. PubMed ID: 33411782
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Motivations for participating in an HIV vaccine efficacy trial.
    Colfax G; Buchbinder S; Vamshidar G; Celum C; McKirnan D; Neidig J; Koblin B; Gurwith M; Bartholow B
    J Acquir Immune Defic Syndr; 2005 Jul; 39(3):359-64. PubMed ID: 15980699
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acceptability of a trial of vaginal progesterone for the prevention of preterm birth among HIV-infected women in Lusaka, Zambia: A mixed methods study.
    Price JT; Mabula-Bwalya CM; Freeman BL; Carda-Auten J; Phiri WM; Chibwe K; Kantumoya P; Vwalika B; Stringer JSA; Golin CE
    PLoS One; 2020; 15(9):e0238748. PubMed ID: 32970697
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Mixed-Methods Study Examining Adherence to and Acceptability of Intravaginal Rings for HIV Prevention: Behavioral Results of MTN-027.
    Bauermeister JA; Golinkoff JM; Carballo-Diéguez A; Giguere R; López D; Hoesley CJ; Chen BA; Anderson P; Dezzutti CS; Strizki J; Sprinkle C; Heard F; Hall W; Jacobson C; Berthiaume J; Mayo A; Richardson BA; Piper J;
    AIDS Behav; 2020 Feb; 24(2):607-616. PubMed ID: 30877580
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Integrated Bio-behavioral Approach to Improve Adherence to Pre-exposure Prophylaxis and Reduce HIV Risk in People Who Use Drugs: A Pilot Feasibility Study.
    Shrestha R; Altice FL; Karki P; Copenhaver MM
    AIDS Behav; 2018 Aug; 22(8):2640-2649. PubMed ID: 29582199
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adherence to pre-exposure prophylaxis among men who have sex with men: A prospective cohort study.
    Qu D; Zhong X; Xiao G; Dai J; Liang H; Huang A
    Int J Infect Dis; 2018 Oct; 75():52-59. PubMed ID: 30125688
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preventive misconception as a motivation for participation and adherence in microbicide trials: evidence from female participants and male partners in Malawi and Zimbabwe.
    Woodsong C; Alleman P; Musara P; Chandipwisa A; Chirenje M; Martinson F; Hoffman I
    AIDS Behav; 2012 Apr; 16(3):785-90. PubMed ID: 21863339
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preferred Physical Characteristics of Vaginal Film Microbicides for HIV Prevention in Pittsburgh Women.
    Fan MD; Kramzer LF; Hillier SL; Chang JC; Meyn LA; Rohan LC
    Arch Sex Behav; 2017 May; 46(4):1111-1119. PubMed ID: 27571742
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Maximizing participant retention in a phase 2B HIV prevention trial in Kampala, Uganda: The MTN-003 (VOICE) Study.
    Wynne J; Muwawu R; Mubiru MC; Kamira B; Kemigisha D; Nakyanzi T; Kabwigu S; Nakabiito C; Kiweewa Matovu F
    HIV Clin Trials; 2018 Oct; 19(5):165-171. PubMed ID: 30370830
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Associations between perceived barriers and benefits of using HIV pre-exposure prophylaxis and medication adherence among men who have sex with men in Western China.
    Hu Y; Zhong XN; Peng B; Zhang Y; Liang H; Dai JH; Zhang JY; Huang AL
    BMC Infect Dis; 2018 Nov; 18(1):575. PubMed ID: 30442106
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Protocol for an open-label, single-arm trial of HIV pre-exposure prophylaxis (PrEP) among people at high risk of HIV infection: the NSW Demonstration Project PRELUDE.
    Vaccher S; Grulich A; McAllister J; Templeton DJ; Bloch M; McNulty A; Holden J; Poynten IM; Prestage G; Zablotska I;
    BMJ Open; 2016 Jun; 6(6):e012179. PubMed ID: 27324719
    [TBL] [Abstract][Full Text] [Related]  

  • 39. "It Was Not My Aim to Sleep There": The Impact of Timing and Location of Sex on Adherence to Coitally-Dependent HIV Pre-exposure Prophylaxis.
    Scorgie F; Stadler J; Baron D; Ju S; Ikaneng T; Mabude Z; Makgopa S; Malefo MA; Manenzhe KN; Mazibuko T; Ntjana H; Nkala B; Palanee-Phillips T; Gray G; Rees H; Delany-Moretlwe S
    AIDS Behav; 2018 Nov; 22(11):3692-3704. PubMed ID: 29909589
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Perspectives from Young South African and Zimbabwean Women on Attributes of Four (Placebo) Vaginal Microbicide Delivery Forms.
    Weinrib R; Browne EN; Shapley-Quinn MK; van der Straten A; Beksinska M; Mgodi N; Musara P; Mphili N; Schwartz JL; Ju S; Hanif H; Montgomery ET;
    AIDS Behav; 2020 Feb; 24(2):637-647. PubMed ID: 31254190
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.